Thomas O Bergmeijer, Jean-Luc Reny, Ruth E Pakyz, Li Gong, Joshua P Lewis, Eun-Young Kim, Daniel Aradi, Israel Fernandez-Cadenas, Richard B Horenstein, Ming Ta Michael Lee, Ryan M Whaley, Joan Montaner, Gian Franco Gensini, John H Cleator, Kiyuk Chang, Lene Holmvang, Willibald Hochholzer, Dan M Roden, Stefan Winter, Russ B Altman, Dimitrios Alexopoulos, Ho-Sook Kim, Jean-Pierre Déry, Meinrad Gawaz, Kevin Bliden, Marco Valgimigli, Rossella Marcucci, Gianluca Campo, Elke Schaeffeler, Nadia P Dridi, Ming-Shien Wen, Jae Gook Shin, Tabassome Simon, Pierre Fontana, Betti Giusti, Tobias Geisler, Michiaki Kubo, Dietmar Trenk, Jolanta M Siller-Matula, Jurriën M Ten Berg, Paul A Gurbel, Jean-Sebastien Hulot, Braxton D Mitchell, Matthias Schwab, Marylyn DeRiggi Ritchie, Teri E Klein, Alan R Shuldiner
Journal: American heart journal 2019;198():152-159
PMID: 29653637
RATIONALE
The P2Y receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet inhibition by clopidogrel shows wide interpatient variability, and high on-treatment platelet reactivity is a risk factor for atherothrombotic events, particularly in high-risk populations. CYP2C19 polymorphism plays an important role in this variability, but heritability estimates suggest that additional genetic variants remain unidentified. The aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify genetic determinants of clopidogrel pharmacodynamics and clinical response.
STUDY DESIGN
Based on the data published on www.clinicaltrials.gov, clopidogrel intervention studies containing genetic and platelet function data were identified for participation. Lead investigators were invited to share DNA samples, platelet function test results, patient characteristics, and cardiovascular outcomes to perform candidate gene and genome-wide studies.
RESULTS
In total, 17 study sites from 13 countries participate in the ICPC, contributing individual patient data from 8,829 patients. Available adenosine diphosphate-stimulated platelet function tests included vasodilator-stimulated phosphoprotein assay, light transmittance aggregometry, and the VerifyNow P2Y assay. A proof-of-principle analysis based on genotype data provided by each group showed a strong and consistent association between CYP2C19*2 and platelet reactivity (P value=5.1 × 10).
CONCLUSION
The ICPC aims to identify new loci influencing clopidogrel efficacy by using state-of-the-art genetic approaches in a large cohort of clopidogrel-treated patients to better understand the genetic basis of on-treatment response variability.
Copyright © 2017 Elsevier Inc. All rights reserved.
Full Text Sources:
Medical:
Other Literature Sources:
Molecular Biology Databases:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.